131 related articles for article (PubMed ID: 29372493)
21. Low serum level of miR-485-3p predicts poor survival in patients with glioblastoma.
Wang ZQ; Zhang MY; Deng ML; Weng NQ; Wang HY; Wu SX
PLoS One; 2017; 12(9):e0184969. PubMed ID: 28931080
[TBL] [Abstract][Full Text] [Related]
22. [The phenomenon of long-term survival in glioblastoma patients. Part I: the role of clinical and demographic factors and an IDH1 mutation (R 132 H)].
Goryaynov SA; Gol'dberg MF; Golanov AV; Zolotova SV; Shishkina LV; Ryzhova MV; Pitskhelauri DI; Zhukov VY; Usachev DY; Belyaev AY; Kondrashov AV; Shurkhay VA; Potapov AA
Zh Vopr Neirokhir Im N N Burdenko; 2017; 81(3):5-16. PubMed ID: 28665384
[TBL] [Abstract][Full Text] [Related]
23. Managing hyponatraemia secondary to primary polydipsia: beware too rapid correction of hyponatraemia.
Boehm E; Kumar S; Nankervis A; Colman P
Intern Med J; 2017 Aug; 47(8):956-959. PubMed ID: 28782208
[TBL] [Abstract][Full Text] [Related]
24. Hyponatremia in cirrhosis: Risk factors and prognostic value.
Ennaifer R; Cheikh M; Romdhane H; El Elj R; Ben Nejma H; Bougassas W; Bel Hadj N
Tunis Med; 2016 May; 94(5):401-405. PubMed ID: 27801493
[TBL] [Abstract][Full Text] [Related]
25. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
[TBL] [Abstract][Full Text] [Related]
26. Phosphorylated Hsp27 is mutually exclusive with ATRX loss and the IDH1
Cai HQ; Wang PF; Zhang HP; Cheng ZJ; Li SW; He J; Zhang Y; Hao JJ; Wang MR; Yan CX; Wan JH
J Clin Pathol; 2018 Aug; 71(8):702-707. PubMed ID: 29550762
[TBL] [Abstract][Full Text] [Related]
27. Factors predicting postoperative hyponatremia and efficacy of hyponatremia management strategies after more than 1000 pituitary operations.
Jahangiri A; Wagner J; Tran MT; Miller LM; Tom MW; Kunwar S; Blevins L; Aghi MK
J Neurosurg; 2013 Dec; 119(6):1478-83. PubMed ID: 23971964
[TBL] [Abstract][Full Text] [Related]
28. Epileptic features and survival in glioblastomas presenting with seizures.
Toledo M; Sarria-Estrada S; Quintana M; Maldonado X; Martinez-Ricarte F; Rodon J; Auger C; Aizpurua M; Salas-Puig J; Santamarina E; Martinez-Saez E
Epilepsy Res; 2017 Feb; 130():1-6. PubMed ID: 28073027
[TBL] [Abstract][Full Text] [Related]
29. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
[TBL] [Abstract][Full Text] [Related]
30. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy.
Millward CP; Brodbelt AR; Haylock B; Zakaria R; Baborie A; Crooks D; Husband D; Shenoy A; Wong H; Jenkinson MD
Acta Neurochir (Wien); 2016 Oct; 158(10):1943-53. PubMed ID: 27526690
[TBL] [Abstract][Full Text] [Related]
31. [Desmopressin for nocturia in the old: an inappropriate treatment due to the high risk of side-effects?].
ten Doesschate T; Reichert LJ; Claassen JA
Tijdschr Gerontol Geriatr; 2010 Dec; 41(6):256-61. PubMed ID: 21229778
[TBL] [Abstract][Full Text] [Related]
32. Desmopressin acetate (DDAVP)-associated hyponatremia and brain damage: a case series.
Achinger SG; Arieff AI; Kalantar-Zadeh K; Ayus JC
Nephrol Dial Transplant; 2014 Dec; 29(12):2310-5. PubMed ID: 25107337
[TBL] [Abstract][Full Text] [Related]
33. Severe hyponatremia due to desmopressin.
Kelleher HB; Henderson SO
J Emerg Med; 2006 Jan; 30(1):45-7. PubMed ID: 16434334
[TBL] [Abstract][Full Text] [Related]
34. Hyponatremia: case vignettes.
Mount DB; Krahn TA
Semin Nephrol; 2009 May; 29(3):300-17. PubMed ID: 19523576
[TBL] [Abstract][Full Text] [Related]
35. Prognostic relevance of epilepsy at presentation in glioblastoma patients.
Berendsen S; Varkila M; Kroonen J; Seute T; Snijders TJ; Kauw F; Spliet WG; Willems M; Poulet C; Broekman ML; Bours V; Robe PA
Neuro Oncol; 2016 May; 18(5):700-6. PubMed ID: 26420896
[TBL] [Abstract][Full Text] [Related]
36. Radiological features combined with IDH1 status for predicting the survival outcome of glioblastoma patients.
Wang K; Wang Y; Fan X; Wang J; Li G; Ma J; Ma J; Jiang T; Dai J
Neuro Oncol; 2016 Apr; 18(4):589-97. PubMed ID: 26409566
[TBL] [Abstract][Full Text] [Related]
37. The use of vasopressin receptor antagonists in hyponatremia.
Khanna A; Menon MC
Curr Opin Investig Drugs; 2010 Sep; 11(9):1007-14. PubMed ID: 20730695
[TBL] [Abstract][Full Text] [Related]
38. Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide.
Redjal N; Reinshagen C; Le A; Walcott BP; McDonnell E; Dietrich J; Nahed BV
J Neurooncol; 2016 May; 127(3):505-14. PubMed ID: 26830093
[TBL] [Abstract][Full Text] [Related]
39. Malignancy associated SIADH: Characterization and clinical implications.
Goldvaser H; Rozen-Zvi B; Yerushalmi R; Gafter-Gvili A; Lahav M; Shepshelovich D
Acta Oncol; 2016; 55(9-10):1190-1195. PubMed ID: 27142293
[TBL] [Abstract][Full Text] [Related]
40. Peritumoral edema shown by MRI predicts poor clinical outcome in glioblastoma.
Wu CX; Lin GS; Lin ZX; Zhang JD; Liu SY; Zhou CF
World J Surg Oncol; 2015 Mar; 13():97. PubMed ID: 25886608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
